Oakville, Ontario–(Newsfile Corp. – June 29, 2023) – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company“), a clinical-stage life sciences company focused on...
Initiated patient enrollment in a Phase II open-label clinical trial investigating the safety, tolerability, and efficacy of CardiolRx™ in patients with recurrent pericarditis – a debilitating...
Results Demonstrate Cannabidiol Improved Cardiac Function, Reduced its Inflammatory State, and Prevented the Development of Hypertrophy and Fibrosis in Heart Tissue Data Presented at The American...
The Cleveland Clinic Recruits First Participant in the Multi-center U.S. Study Oakville, Ontario–(Newsfile Corp. – January 17, 2023) – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)...
The Cleveland Clinic and the Mayo Clinic Study Sites have been Initiated and are Eligible to Recruit Participants Initiation of Additional U.S. Cardiovascular Research Centers is...
Oakville, Ontario–(Newsfile Corp. – November 14, 2022) – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on...
Results Demonstrate Significant Reduction in Pericardial Effusion and Thickness and Significant Suppression of Key Inflammatory Markers IL-1β and IL-6 Data Presented at The American Heart Association...
Discontinues LANCER Trial due to Lack of Eligible Patients for Recruitment Cash Runway Now Extends into 2026 Oakville, Ontario–(Newsfile Corp. – October 25, 2022) – Cardiol...
Data Presented at The Annual Scientific Meeting of the Heart Failure Society of America September 30th, 2022 Oakville, Ontario–(Newsfile Corp. – October 3, 2022) – Cardiol...
Oakville, Ontario–(Newsfile Corp. – September 28, 2022) – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on...